Showing 3951-3960 of 10107 results for "".
- Aesthetics Biomedical Taps Molly Sims As New SoME Skincare Brand Ambassadorhttps://practicaldermatology.com/news/aesthetics-biomedical-taps-molly-sims-as-new-some-skincare-brand-ambassador/2460290/Molly Sims is Brand Ambassador for Aesthetics Biomedical’s SoME Skincare That's All You, a patented personalized Platelet Rich Plasma (PRP) skincare for at-home use. SoME That's All You is com
- Triple-Combination Acne Treatment Shows Equal Efficacy Across Sexeshttps://practicaldermatology.com/news/triple-combination-acne-treatment-shows-equal-efficacy-across-sexes/2468352/A post hoc analysis of two phase 3 studies showed clindamycin phosphate 1.2%/adapalene 0.15%/benzoyl peroxide 3.1% gel (CAB) had s
- Call for Papers: JMIR Dermatology Special Theme Issue on Teledermatologyhttps://practicaldermatology.com/news/call-for-papers-jmir-dermatology-special-theme-issue-on-teledermatology/2461734/JMIR Dermatology—the official journal of the International Society of Teledermatology (ISTD)—and the journal’s guest editors welcome submissions to
- UV Index Today is Helping to Reduce Skin Cancer Rates with Web Technologyhttps://practicaldermatology.com/news/uv-index-today-is-helping-to-reduce-skin-cancer-rates-with-web-technology/2460891/UV Index Today launched their free UV forecasting service to help people track the sun’s ultraviolet radiation
- Sirnaomics Doses First Patient in Phase 2b Study of STP705 for Treatment of Squamous Cell Skin Cancerhttps://practicaldermatology.com/news/sirnaomics-doses-first-patient-in-phase-2b-study-of-stp705-for-treatment-of-squamous-cell-skin-cancer/2460857/Sirnaomics, Inc. dosed the first patient in a Phase 2b study of the company's drug candidate, STP705, for the trea
- Acne News: Clascoterone Cream 1% Exhibits Long-Term Safety for Treatment of Acnehttps://practicaldermatology.com/news/acne-news-clascoterone-cream-1-exhibits-long-term-safety-for-treatment-of-acne/2460442/Cassiopea SpA’s Clascoterone cream 1% is safe for the treatment of acne with low rates of treatment-related adverse events, according to a study in the online issue of
- White Paper: It's Time to Start Prescribing Biosimilarshttps://practicaldermatology.com/news/white-paper-its-time-to-start-prescribing-biosimilars/2457843/The American College of Rheumatology’s new white paper, “The Science Behind Biosimilars — Entering a New Era of Biologic Therapy,
- Suneva Medical's Bellafill Approved to Treat Acne Scarshttps://practicaldermatology.com/news/suneva-medicals-bellafill-approved-to-treat-acne-scars/2459034/Suneva Medical, Inc.'s Bellafill® is now the only filler on the market approved for the treatment of acne scars. FDA granted approval for Bellafil
- Heart Transplant Patients Show Increased Skin Cancer Incidence: Meta-Analysishttps://practicaldermatology.com/news/heart-transplant-patients-show-increased-skin-cancer-incidence-meta-analysis/2470902/Heart transplant (HTx) recipients face a 16% overall risk of developing skin cancer, with squamous and basal cell carcinomas being the most common forms, a new meta-analysis indicated. "Studies have shown that patients who undergo HTx are at an increased risk for developing skin cancer," t
- Report: Global Skin Cancer Treatment Market to Hit $14.5 Billion by 2031https://practicaldermatology.com/news/global-skin-cancer-treatment-market-poised-rapid-growth-expected-hit-145-billion-2031/2468065/A recent report from Allied Analytics said the global skin cancer treatment market is projected to nearly double, reaching $14.5 billion by 2031, driven by an increasing incidence of skin cancer and advancements in treatment options. The $7.2 billion (2021) treatment market, according to t